CABALETTA BIO, INC. (CABA) News
Filter CABA News Items
CABA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CABA News Highlights
- CABA's 30 day story count now stands at 2.
- Over the past 21 days, the trend for CABA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about CABA are BIO, FL and NOV.
Latest CABA News From Around the Web
Below are the latest news stories about CABALETTA BIO INC that investors may wish to consider to help them evaluate CABA as an investment opportunity.
Cabaletta Bio Stock (NASDAQ:CABA): Analysts Expect More Gains Despite Massive RallyCabaletta Bio (NASDAQ:CABA) shares have staged an enormous rally in the last year to reach an all-time high, but analysts still see plenty of gains ahead. The clinical-stage biotech firm, which discovers and develops T-cell therapies to treat patients with a variety of autoimmune diseases, has seen its shares more than triple in price over the past 12 months. Biotech stocks have a history of dramatic spikes and valleys owing to the promise—and potential letdown—of potentially influential new dru |
Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx ConferencePHILADELPHIA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29, 2023 at 8:20 a.m. ET in Miami, FL. A live webcast of the presentation w |
Cabaletta Bio Inc (CABA) Reports Q3 2023 Financial Results and Business ProgressStrategic Advances in Autoimmune Disease Treatments and Financial Health |
Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update– Initial clinical data from CABA-201 treated patients in Phase 1/2 trials for lupus and/or myositis expected in the first half of 2024, with the first lupus clinical site actively recruiting patients – – Expanded CABA-201 clinical development program within rheumatology and into neurology with additional IND clearances in systemic sclerosis and generalized myasthenia gravis – – CABA-201 now being evaluated in four concurrent Phase 1/2 studies, each with an initial dose of 1 x 106 cells/kg and a |
Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle PlatformSOUTH SAN FRANCISCO, Calif., November 06, 2023--Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, and Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced Cabaletta will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle™, |
Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis– First cleared CD19-CAR T IND application for generalized myasthenia gravis announced in the U.S. and fourth IND clearance for CABA-201 across a broad range of autoimmune diseases – – Clearance expands the clinical development of CABA-201 beyond rheumatology into neurology – – Phase 1/2 clinical trial evaluating CABA-201 in generalized myasthenia gravis features parallel cohort design and a starting dose consistent with the previously announced Phase 1/2 trials of CABA-201 for lupus, myositis a |
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in NovemberPHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the Company will participate in three upcoming investor conferences in November: Guggenheim 5th Annual Inflammation, Neurology, & Immunology Conference: Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside cha |
Are Medical Stocks Lagging Cabaletta Bio (CABA) This Year?Here is how Cabaletta Bio, Inc. (CABA) and KalVista Pharmaceuticals, Inc. (KALV) have performed compared to their sector so far this year. |
Pleasing Signs As A Number Of Insiders Buy Cabaletta Bio StockIt is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it... |
QIAGEN (QGEN) Extends the AI-Powered QCI Interpret SoftwareQIAGEN's (QGEN) NGS interpretation software, QCI Interpret, now covers the whole exome due to additional AI capabilities. |